- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00712803
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3-3'Ddelta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dengue viruses cause dengue fever and the more severe dengue hemorrhagic fever/shock syndrome. More than 2 billion people living in tropical and subtropical regions of the world are at risk of dengue virus infection, which is the leading cause of hospitalization and death in children in several tropical Asian countries. This study will evaluate the safety and immunogenicity of a live attenuated dengue virus vaccine called rDEN3-3'D4delta30. This vaccine is derived from rDEN4delta30, another dengue virus vaccine candidate that has been shown to be safe and immunogenic in Phase I and II trials in healthy adults.
There will be two groups in this study. Participants in Group 1 will be randomly assigned to receive rDEN3-3'D4delta30 vaccine or placebo at study entry. The dosing for Group 2 will be determined by a safety review of all participants in Group 1. If less than 90 % of the Group 1 participants seroconvert to DEN3 participants in Group 2 will receive a higher dose of rDEN3-3'D4delta30. If at least 90 % of Group 1 participants seroconvert to DEN3, participants in Group 2 will receive a lower dose of rDEN3-3'D4delta30.
All participants will be required to monitor their temperature three times each day for the first 16 days following each vaccination. Study visits will occur 30 minutes following each vaccination and every other day after vaccination until Day 16, followed by four additional visits at selected days through Day 180. Blood collection, vital signs measurement, and a targeted physical exam will occur at each study visit. Some participants will be asked to undergo a skin biopsy or additional blood collection at selected visits.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- Center for Immunization Research, Johns Hopkins School of Public Health
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Center for Immunization Research, Johns Hopkins University of Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- General good health
- Available for the duration of the study
- Willing to use accepted forms of contraception
Exclusion Criteria:
- Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease by history, physical examination, or laboratory studies including urinalysis
- Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, may interfere with the study
- Certain abnormal laboratory values. More information on this criterion can be found in the protocol.
- Medical, work, or family problems as a result of alcohol or illegal drug use within 12 months of study entry
- History of severe allergy or anaphylaxis
- Severe asthma requiring an emergency room visit or hospitalization within 6 months of study entry
- HIV infected
- Hepatitis C virus infected
- Hepatitis B surface antibody positive
- Known immunodeficiency syndrome
- Use of corticosteroids or immunosuppressive drugs 30 days prior to study entry. Participants who have used topical or nasal corticosteroids are not excluded.
- Receipt of live vaccine within 4 weeks of study entry
- Receipt of killed vaccine within 2 weeks of study entry
- Absence of spleen
- Plan to travel to an area where dengue virus is common
- Any investigational product within 30 days of study entry
- Other condition that, in the opinion of the investigator, would interfere with the study
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
One subcutaneous vaccination (10^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
|
Live attenuated 10^3 dose of rDEN3-3'D4delta30 vaccine.
Live attenuated 10^5 dose of rDEN3-3'D4delta30 vaccine.
Live attenuated 10^1 dose of rDEN3-3'D4delta30 vaccine.
|
EXPERIMENTAL: 2
One subcutaneous vaccination (10^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
|
Live attenuated 10^3 dose of rDEN3-3'D4delta30 vaccine.
Live attenuated 10^5 dose of rDEN3-3'D4delta30 vaccine.
Live attenuated 10^1 dose of rDEN3-3'D4delta30 vaccine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and immunogenicity, as assessed by neutralizing antibody titers
Time Frame: At 4 weeks and 6 weeks after vaccination
|
At 4 weeks and 6 weeks after vaccination
|
Frequency of vaccine related adverse events as graded by severity
Time Frame: Throughout study
|
Throughout study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency, quantity, and duration of viremia after a single dose of vaccine
Time Frame: Throughout study
|
Throughout study
|
Number of vaccines infected with rDEN3-3'D4delta30
Time Frame: Throughout study
|
Throughout study
|
Infectivity rates, safety, and immunogenicity of a single dose of rDEN3-3'D4delta30 vaccine
Time Frame: Throughout study
|
Throughout study
|
Durability of antibody response
Time Frame: At 26 Weeks after vaccination
|
At 26 Weeks after vaccination
|
Obtain an estimate for the Human Infectious Dose-50% (HID50) idf dose dependent infectivity is observed
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg. 2004 Dec;71(6):811-21.
- Chaturvedi UC, Shrivastava R, Nagar R. Dengue vaccines: problems and prospects. Indian J Med Res. 2005 May;121(5):639-52.
- Guzman MG, Mune M, Kouri G. Dengue vaccine: priorities and progress. Expert Rev Anti Infect Ther. 2004 Dec;2(6):895-911. doi: 10.1586/14789072.2.6.895.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIR 252
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Shock SyndromePuerto Rico
-
University of the PhilippinesWorld Health Organization; University of North Carolina; International Vaccine... and other collaboratorsActive, not recruitingDengue | Dengue Fever | Severe Dengue | Virologically-confirmed Dengue
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusPuerto Rico, Colombia, Mexico, Honduras
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia
Clinical Trials on rDEN3-3'D4delta30
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Eastern Mediterranean UniversityCompletedOverweight and ObesityCyprus
-
Edwards LifesciencesActive, not recruitingHeart Diseases | Aortic Stenosis, SevereUnited States, Canada
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Edwards LifesciencesActive, not recruitingAortic Valve Stenosis | Aortic Stenosis, CalcificUnited States, Australia, Japan, Canada, Netherlands, Switzerland
-
University of AarhusSteno Diabetes Center Aarhus, Aarhus University Hospital, Denmark; Department...CompletedKetosis | Postprandial Hyperglycemia | Glucose Metabolism Disorders (Including Diabetes Mellitus)Denmark
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve DegenerationUnited States
-
Sheffield Children's NHS Foundation TrustUniversity of SheffieldCompletedAcute BronchiolitisUnited Kingdom
-
UNICANCERCompleted